Effect of perioperative β blockade in patients with diabetes undergoing major non-cardiac surgery: randomised placebo controlled, blinded multicentre trial
Top Cited Papers
- 22 June 2006
- Vol. 332 (7556) , 1482
- https://doi.org/10.1136/bmj.332.7556.1482
Abstract
Objectives To evaluate the long term effects of perioperative β blockade on mortality and cardiac morbidity in patients with diabetes undergoing major non-cardiac surgery. Design Randomised placebo controlled and blinded multicentre trial. Analyses were by intention to treat. Setting University anaesthesia and surgical centres and one coordinating centre. Participants 921 patients aged > 39 scheduled for major non-cardiac surgery. Interventions 100 mg metoprolol controlled and extended release or placebo administered from the day before surgery to a maximum of eight perioperative days. Main outcome measures The composite primary outcome measure was time to all cause mortality, acute myocardial infarction, unstable angina, or congestive heart failure. Secondary outcome measures were time to all cause mortality, cardiac mortality, and non-fatal cardiac morbidity. Results Mean duration of intervention was 4.6 days in the metoprolol group and 4.9 days in the placebo group. Metoprolol significantly reduced the mean heart rate by 11% (95% confidence interval 9% to 13%) and mean blood pressure by 3% (1% to 5%). The primary outcome occurred in 99 of 462 patients in the metoprolol group (21%) and 93 of 459 patients in the placebo group (20%) (hazard ratio 1.06, 0.80 to 1.41) during a median follow-up of 18 months (range 6-30). All cause mortality was 16% (74/462) in the metoprolol group and 16% (72/459) in the placebo group (1.03, 0.74 to 1.42). The difference in risk for the proportion of patients with serious adverse events was 2.4% (− 0.8% to 5.6%). Conclusions Perioperative metoprolol did not significantly affect mortality and cardiac morbidity in these patients with diabetes. Confidence intervals, however, were wide, and the issue needs reassessment. Trial registration Current Controlled Trials ISRCTN58485613 [controlled-trials.com.Keywords
This publication has 22 references indexed in Scilit:
- β blockers for elective surgery in elderly patients: population based, retrospective cohort studyBMJ, 2005
- β2-Adrenergic Receptor Genotype and Survival Among Patients Receiving β-Blocker Therapy After an Acute Coronary SyndromeJAMA, 2005
- Perioperative β-blockade (Pobble) for patients undergoing infrarenal vascular surgery: Results of a randomized double-blind controlled trialJournal of Vascular Surgery, 2005
- The diabetic postoperative mortality and morbidity (DIPOM) trial: rationale and design of a multicenter, randomized, placebo-controlled, clinical trial of metoprolol for patients with diabetes mellitus who are undergoing major noncardiac surgeryAmerican Heart Journal, 2004
- ACC/AHA Guideline Update for Perioperative Cardiovascular Evaluation for Noncardiac Surgery—Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery)Circulation, 2002
- Perioperative β-blocker withdrawal and mortality in vascular surgical patientsAmerican Heart Journal, 2001
- ACC/AHA guidelines as predictors of postoperative cardiac outcomesCanadian Journal of Anesthesia/Journal canadien d'anesthésie, 2000
- Long-term postoperative mortality in diabetic patients undergoing major non-cardiac surgeryEuropean Journal of Anaesthesiology, 1999
- Prophylactic Atenolol Reduces Postoperative Myocardial IschemiaAnesthesiology, 1998
- EQUAL EFFICACY AND IMPROVED TOLERABILITY WITH 50 MG CONTROLLED-RELEASE METOPROLOL COMPARED WITH 100 MG CONVENTIONAL METOPROLOL IN HYPERTENSIVE PATIENTSClinical Journal of Sport Medicine, 1994